Non-Small Cell Lung Cancer (NSCLC)
Symptoms, Doctors, Treatments, Advances & More

Non-Small Cell Lung Cancer (NSCLC) Overview

Save information for later
Sign Up

Learn About Non-Small Cell Lung Cancer (NSCLC)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Non-Small Cell Lung Cancer (NSCLC) Local Doctors?
Elite in Non-Small Cell Lung Cancer (NSCLC)
Elite in Non-Small Cell Lung Cancer (NSCLC)

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Experience:
34+ years
Languages Spoken:
English, Tamil
Offers Telehealth

Suresh Ramalingam is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 34 years. Dr. Ramalingam is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Ramalingam is board certified in American Board Of Internal Medicine, 2003.

Elite in Non-Small Cell Lung Cancer (NSCLC)
Elite in Non-Small Cell Lung Cancer (NSCLC)

Johns Hopkins Bayview Medical Center

300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, 
Baltimore, MD 
Languages Spoken:
English
Offers Telehealth

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is board certified in American Board Of Internal Medicine.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Non-Small Cell Lung Cancer (NSCLC)
Elite in Non-Small Cell Lung Cancer (NSCLC)

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Charu Aggarwal is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Aggarwal is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Aggarwal is board certified in Medical Oncology, 2011. Dr. Aggarwal is currently accepting new patients.

What are the latest Non-Small Cell Lung Cancer (NSCLC) Clinical Trials?
A Randomized Pivotal Study Assessing the Safety and Efficacy of Targeted Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin

Summary: The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIB-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial

Summary: The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include: Can LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combi...